What is Roth Capital’s Estimate for Enovis Q1 Earnings?

Enovis Co. (NYSE:ENOV) – Analysts at Roth Capital issued their Q1 2025 EPS estimates for shares of Enovis in a research report issued on Thursday, February 27th. Roth Capital analyst J. Wittes expects that the company will post earnings of $0.73 per share for the quarter. The consensus estimate for Enovis’ current full-year earnings is $2.79 per share. Roth Capital also issued estimates for Enovis’ Q2 2025 earnings at $0.80 EPS, Q3 2025 earnings at $0.82 EPS and Q4 2025 earnings at $0.88 EPS.

Enovis (NYSE:ENOV) last released its earnings results on Wednesday, February 26th. The company reported $0.98 EPS for the quarter, beating analysts’ consensus estimates of $0.92 by $0.06. Enovis had a positive return on equity of 4.39% and a negative net margin of 5.95%. The company had revenue of $560.98 million during the quarter, compared to the consensus estimate of $555.14 million.

Separately, Needham & Company LLC dropped their target price on shares of Enovis from $65.00 to $64.00 and set a “buy” rating for the company in a research report on Thursday, February 27th.

Enovis Trading Down 2.1 %

Shares of Enovis stock opened at $37.83 on Monday. The firm has a market cap of $2.15 billion, a PE ratio of -17.27 and a beta of 1.94. The company has a quick ratio of 1.12, a current ratio of 2.27 and a debt-to-equity ratio of 0.40. Enovis has a fifty-two week low of $37.60 and a fifty-two week high of $63.96. The business’s fifty day moving average is $44.72 and its two-hundred day moving average is $44.28.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in ENOV. Quadrant Capital Group LLC lifted its position in Enovis by 53.0% in the fourth quarter. Quadrant Capital Group LLC now owns 690 shares of the company’s stock worth $30,000 after purchasing an additional 239 shares during the period. Amalgamated Bank grew its holdings in shares of Enovis by 1.0% during the 4th quarter. Amalgamated Bank now owns 25,887 shares of the company’s stock valued at $1,136,000 after acquiring an additional 264 shares in the last quarter. Pinnacle Bancorp Inc. increased its position in Enovis by 54.5% in the 4th quarter. Pinnacle Bancorp Inc. now owns 850 shares of the company’s stock worth $37,000 after purchasing an additional 300 shares during the last quarter. Arizona State Retirement System increased its holdings in Enovis by 2.6% in the fourth quarter. Arizona State Retirement System now owns 16,208 shares of the company’s stock worth $711,000 after buying an additional 414 shares during the last quarter. Finally, Aigen Investment Management LP raised its holdings in shares of Enovis by 5.1% during the 3rd quarter. Aigen Investment Management LP now owns 8,859 shares of the company’s stock valued at $381,000 after purchasing an additional 430 shares in the last quarter. Institutional investors and hedge funds own 98.45% of the company’s stock.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.